PROTEIN-tyrosine kinase inhibitorsDRUG therapyThe optimal management of advanced non-small cell lung cancer (NSCLC) with noncanonical epidermal growth factor receptor (EGFR) mutations (i.e., exon 19 deletion and exon 21 L858R) is constrained by the heterogeneous behavior of individual uncommon ...
Immune checkpoint inhibitors (ICIs) have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC). In spite of durable responses in some patients, many patients develop early disease progression during the ICI treatment. Thus,
Ig-like-1, Ig-like C2-type 1 region; Ig-like-2, Ig-like C2-type 2 region; LRR, leucine-rich repeat; LRRCT, leucine-rich repeat C-terminal domain; LRRNT, leucine-rich repeat N-terminal domain; TK, tyrosine kinase domain; TM, transmembrane domain. Table 1. Characteristics of NTRK ...
Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype Hematol Oncol, 25 (2007), pp. 1-5 CrossrefView in ScopusGoogle Scholar 21...
inhibitor of FLT3 tyrosine kinase, is currently in PhaseIIIclinicaldevelopment for newly diagnosed patients with FLT3 mutated [...] tipschina.gov.cn tipschina.gov.cn 米哚妥林是一种针对FLT3络氨酸激活酶的定向小分子抑制剂,目前正处于第三阶段临床开发中,给新确诊的FLT3突变急性髓细胞白血病患者服用米哚妥林...
Peretz, Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer. Breast Cancer Res. Treat. 138, 407-413 (2013).Sonnenblick, A.; Uziely, B.; Nechushtan, H.; Kadouri, L.; Galun, E.; Axelrod, J.H.; Katz, D.; Daum, H.;...
We previously reviewed the cardiovascular safety of 16 tyrosine kinase inhibitors (TKIs), approved for use in oncology as of 30 September 2012. Since then, the indications for some of them have been widened and an additional nine TKIs have also been approved as of 30 April 2015. Eight of th...
5.Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update.Nutrition. 2010;26:250-254.[PubMed][DOI][Cited in This Article:2][Cited by in Crossref: 175][Cited by inRCA: 163][Article Influence: 10.2][Reference Citation Analysis (0)] ...
Fig. 1. Domain structure of GSK-3 isoforms: Comparison of domains and phosphorylation sites of the two GSK-3 isoforms Some kinases that phosphorylate GSK-3 isoforms are also shown. GSK-3 = Glycogen synthase kinase-3; Fyn = Proto-oncogene tyrosine-protein kinase; ILK = Integrin-linked kinase...
In coral-DOM, the protein-like components C3 (Tyrosine-like) and C4 (Tryptophan-like) showed higher fluorescence intensities year-round. In algal-DOM, C3 also showed consistently higher fluorescence intensities, but, the fluorescence intensities of the other components showed greater seasonal ...